Advertisement

Topics

Fast track for dementia drug good news for Axovant and new CEO

08:48 EDT 19 Jun 2017 | pharmaphorum

Axovant has gained FDA fast track designation for its pipeline drug nelotanserin, a treatment for visual hallucinations suffered by people with dementia with Lewy bodies (DLB). The condition is the second most common form of progressive dementia a...

Original Article: Fast track for dementia drug good news for Axovant and new CEO

NEXT ARTICLE

More From BioPortfolio on "Fast track for dementia drug good news for Axovant and new CEO"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...